Seed lots were prepared and characterized and a trial lot prepared to optimize processes including inoculation, harvesting clarification, purification and concentration. The same lot was used to Quizartinib ic50 assess the formulation and freeze-drying procedures, as well as to validate quality control tests. A second lot was prepared for toxicity studies in mice and rats in October 2009. These studies revealed no toxic effects at doses higher than the intended human dose. The vaccine was tested in mice challenge

studies (National Institute of Virology, Pune, India) and was found to induce protective immunity against the wild type strain. Ferret challenge studies were conducted with a single dose of LAIV with significant induction of haemagglutination inhibition (HAI) and microneutralization (MN) antibodies and complete protection against virus challenge (Fig. 3 and Table 1). This study was conducted in collaboration with WHO at Viroclinic, The Netherlands. A third lot was prepared and released for clinical trial purposes by the SII quality control laboratory and the Indian National Control Authority (NCA) in January 2010. A Phase I, double-blind randomized study in 50 healthy adults aged 18–49 years compared a placebo and a single dose of the study vaccine [107 of the 50% egg infectious dose (EID50)] INCB018424 to assess safety

over 42 days (CTRI/2010/091/000008). No serious adverse events (SAEs) TCL or unsolicited

events were reported. All solicited reactions were mild in intensity and all were resolved without sequelae within 2–3 days. The Phase II/III double-blind randomized trial involved 330 individuals (110 adults, 110 elderly and 110 adolescents and children ≥3 years) at five sites in India (CTRI/2010/091/000092). Subjects received either a placebo or 107 EID50 dose of the study vaccine. The vaccine was found safe in all age groups. No SAEs were reported and none of the unsolicited events in either group was causally related to the study products. The solicited reactions were similar in both groups, all of which were mild and all resolved without sequelae. Although LAIV has been proved to be highly efficacious in preventing influenza virus infection, the serological correlates of protection are not well established. From studies characterizing the immune response following intranasal administration of LAIVs, cell-mediated immunity (CMI) is considered to have a role in protection in adults and children that cannot be entirely explained by mucosal or serum antibody responses. So far, the role of CMI in protection against clinical influenza has not been established in the field, due to the technical difficulties of using these complex assays. WHO recommended that an appropriate approach to evaluate the immunogenicity of LAIVs in clinical trials would be to show significant uptake (e.